Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial

Bibliographic Details
Title: Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial
Authors: Weiss, Aaron R *, *, Chen, Yen-Lin *, Scharschmidt, Thomas J *, Chi, Yueh-Yun, Tian, Jing, Black, Jennifer O, Davis, Jessica L, Fanburg-Smith, Julie C, Zambrano, Eduardo, Anderson, James, Arens, Robin, Binitie, Odion, Choy, Edwin, Davis, Justin W, Hayes-Jordan, Andrea, Kao, Simon C, Kayton, Mark L, Kessel, Sandy, Lim, Ruth, Meyer, William H, Million, Lynn, Okuno, Scott H, Ostrenga, Andrew, Parisi, Marguerite T, Pryma, Daniel A, Randall, R Lor, Rosen, Mark A, Schlapkohl, Mary, Shulkin, Barry L, Smith, Ethan A, Sorger, Joel I, Terezakis, Stephanie, Hawkins, Douglas S, Spunt, Sheri L, Wang, Dian
Source: In The Lancet Oncology August 2020 21(8):1110-1122
Database: ScienceDirect
More Details
ISSN:14702045
DOI:10.1016/S1470-2045(20)30325-9
Published in:The Lancet Oncology
Language:English